

# Rosario Foti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5889993/publications.pdf>

Version: 2024-02-01

43  
papers

1,194  
citations

471061

17  
h-index

377514

34  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1948  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and reduction of the response rate to anti-tumor necrosis factor in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	1.5	170
2	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1970-1977.	6.7	134
3	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
4	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
5	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020, 80, 1929-1946.	4.9	74
6	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	1.0	73
7	Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. <i>Blood</i> , 2015, 126, 1163-1171.	0.6	69
8	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	1.6	63
9	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
10	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. <i>RMD Open</i> , 2021, 7, e001519.	1.8	32
11	Usefulness of exercise tomographic myocardial perfusion imaging for detection of restenosis after coronary stent implantation. <i>American Journal of Cardiology</i> , 2000, 85, 1362-1364.	0.7	28
12	Accuracy of 99mTc-tetrofosmin myocardial tomography in the evaluation of coronary artery disease. <i>Journal of Nuclear Cardiology</i> , 1999, 6, 183-189.	1.4	27
13	Disease knowledge index and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	0.8	25
14	Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 186-200.	0.4	23
15	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	0.8	21
16	Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach. <i>Advances in Therapy</i> , 2019, 36, 806-816.	1.3	20
17	Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. <i>Rheumatology International</i> , 2017, 37, 245-249.	1.5	19
18	Comparison of technetium 99m-tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. <i>Journal of Nuclear Cardiology</i> , 1998, 5, 56-63.	1.4	18

#	ARTICLE	IF	CITATIONS
19	Cardiac hydatid cyst with clinical features resembling subaortic stenosis. <i>American Heart Journal</i> , 1989, 117, 1385-1387.	1.2	17
20	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018, 57, vii11-vii22.	0.9	17
21	Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment. <i>Clinical Rheumatology</i> , 2019, 38, 2355-2362.	1.0	15
22	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018, 85, 455-459.	0.8	14
23	Accuracy of exercise testing in the assessment of the severity of myocardial ischemia as determined by means of technetium-99m tetrofosmin SPECT scintigraphy. <i>Journal of Nuclear Cardiology</i> , 2000, 7, 575-583.	1.4	13
24	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
25	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1497.	1.6	12
26	High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. <i>Clinical Rheumatology</i> , 2014, 33, 31-37.	1.0	10
27	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020, 40, 263-272.	1.5	10
28	The UltraSound-Clinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 619-629.	1.6	9
29	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	1.0	7
30	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
31	Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 558838.	1.3	6
32	Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity. <i>Diagnostics</i> , 2020, 10, 404.	1.3	5
33	Long-Term angiographic follow-up after successful repeat balloon angioplasty for in-stent restenosis. <i>Clinical Cardiology</i> , 2001, 24, 334-340.	0.7	4
34	Long-term survival in a patient with muscle-“eye”-brain disease. <i>Neurological Sciences</i> , 2015, 36, 2147-2149.	0.9	3
35	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020, 35, 163-169.	0.3	3
36	Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 297-301.	0.1	3

#	ARTICLE	IF	CITATIONS
37	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. Expert Opinion on Drug Safety, 2022, 21, 613-623.	1.0	3
38	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. Clinical Rheumatology, 2022, 41, 3219-3225.	1.0	3
39	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
40	Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry. Indian Journal of Rheumatology, 2019, 14, 271.	0.2	1
41	AB0761â€¦SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN REAL LIFE: AN ITALIAN EXPERIENCE. , 2019, , .		0
42	AB0253â€¦BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		0
43	Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. Hemato, 2021, 2, 347-352.	0.2	0